GlassScriptPhysician profile
Joseph Radzwilka
NPI 1871520957
$2,599.71
in general payments reported to CMS, 2019-2025
32 companies · $21.33 in 2025
The $21.33 reported for 2025 was less than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $242 · 2021: $148 · 2022: $593 · 2023: $1,087 · 2024: $22.20 · 2025: $21.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $423.54 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $358.83 | 2019-2023 | Repatha, Otezla |
| Abbvie INC. | $252.28 | 2019-2025 | |
| Lilly USA, LLC | $239.30 | 2020-2023 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $185.94 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $125.62 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.06 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $106.47 | 2020-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $105.76 | 2019-2023 | Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $63.47 | 2019-2023 | Spravato |
| Biohaven Pharmaceuticals, INC. | $52.33 | 2021 | |
| Avanir Pharmaceuticals, INC. | $47.43 | 2019-2022 | |
| Radius Health, INC. | $47.25 | 2022-2023 | Tymlos |
| Abbott Laboratories | $47.16 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Almatica Pharma LLC | $45.48 | 2022-2023 | Loreev Xr |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $35.58 | 2022 | |
| Pfizer INC. | $35.00 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $33.04 | 2022-2023 | Quviviq |
| Sanofi Pasteur INC. | $31.19 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.17 | 2022-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $26.07 | 2019 | |
| Astellas Pharma US INC | $25.29 | 2019 | |
| Shield Therapeutics INC | $24.33 | 2023 | Accrufer |
| Boston Scientific Corporation | $24.24 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $23.59 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.37 | 2023 | Rexulti |
| Daiichi Sankyo INC. | $19.95 | 2022 | |
| Exact Sciences Corporation | $14.68 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $13.32 | 2019 | |
| Amarin Pharma, INC. | $12.36 | 2020 | |
| Philips North America LLC | $11.55 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Radzwilka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.